U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Approval Year

Substance Class Protein
Created
by admin
on Mon Oct 21 19:43:56 UTC 2019
Edited
by admin
on Mon Oct 21 19:43:56 UTC 2019
Protein Type ENZYME
Protein Sub Type CYTOCHROME P450
Sequence Origin HUMAN
Sequence Type COMPLETE
Record UNII
8E4LAA4357
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CYTOCHROME P450 2D6
Common Name English
CYTOCHROME P450, FAMILY 2, SUBFAMILY D, POLYPEPTIDE 6
Common Name English
CYTOCHROME P 450 2D6
Common Name English
HUMAN CYTOCHROME P450 2D6
Common Name English
CYP2D6
Common Name English
Code System Code Type Description
PUBCHEM
121225712
Created by admin on Mon Oct 21 19:43:56 UTC 2019 , Edited by admin on Mon Oct 21 19:43:56 UTC 2019
PRIMARY
CAS
330597-62-1
Created by admin on Mon Oct 21 19:43:56 UTC 2019 , Edited by admin on Mon Oct 21 19:43:56 UTC 2019
PRIMARY
UNIPROT
P10635
Created by admin on Mon Oct 21 19:43:56 UTC 2019 , Edited by admin on Mon Oct 21 19:43:56 UTC 2019
PRIMARY
Related Record Type Details
SUBSTRATE -> METABOLIC ENZYME
MAJOR
SUBSTRATE -> METABOLIC ENZYME
At higher than clinical concentrations, ixazomib was metabolized by multiple CYP isoforms with estimated relative contributions of 3A4 (42%), 1A2 (26%), 2B6 (16%), 2C8 (6%), 2D6 (5%), 2C19 (5%) and 2C9 (< 1%).
INHIBITOR -> METABOLIC ENZYME
LOW
Ki
NON-INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
Pharmacological action: Tricyclic antidepressant drug (TCA)
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
Lofexidine exposures were approximately 30% greater with co-administration of paroxetine a strong inhibitor of CYP2D6.
MAJOR
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
IN-VITRO
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
IC50
INHIBITOR -> METABOLIC ENZYME
Ki
SUBSTRATE -> METABOLIC ENZYME
MAJOR
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
WEAK INHIBITOR
INHIBITOR -> METABOLIC ENZYME
POTENT
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
SUBSTRATE -> METABOLIC ENZYME
MINOR
INHIBITOR -> METABOLIC ENZYME
Strong Inhibitors(2) 5-fold increase in AUC or > 80% decrease in CL
MAJOR
SUBSTRATE -> METABOLIC ENZYME
MINOR
INHIBITOR -> METABOLIC ENZYME
POTENT
INHIBITOR -> METABOLIC ENZYME
Ki
SUBSTRATE -> METABOLIC ENZYME
MINOR
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
POTENT
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MAJOR
INHIBITOR -> METABOLIC ENZYME
Abiraterone is an inhibitor of CYP2D6, in vivo.
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
WEAK INHIBITOR->METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: 2- and 8-Hydroxylation
INHIBITOR -> METABOLIC ENZYME
Interaction with CYP2D6 substrates is not expected to be clinically significant.
MINOR
IC50
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
POTENT
SUBSTRATE -> METABOLIC ENZYME
MAJOR
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: N-demethylation
NON-INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MAJOR
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: 2-Hydroxylation
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> TARGET
SUBSTRATE -> METABOLIC ENZYME
MAJOR
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: N-demethylation Pharmacological action: Phenothiazine antipsychotic
SUBSTRATE
Unidentified
INHIBITOR -> METABOLIC ENZYME
In vitro studies have shown that vilazodone is a moderate inhibitor of CYP2C19 and CYP2D6
NON-SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
SUBSTRATE -> METABOLIC ENZYME
MAJOR
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
POTENT
INHIBITOR -> METABOLIC ENZYME
POTENT
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
Eliglustat also exhibited time-dependent inhibition (TDI) of CYP2D6.
Ki
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: Demethylatio
NON-SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MAJOR
INHIBITOR -> METABOLIC ENZYME
CYP2C8
IC50
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
Metabolizing reaction by CYP2D6: O-demethylation
SUBSTRATE -> METABOLIC ENZYME
WEAK
SUBSTRATE -> METABOLIC ENZYME
MAJOR
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
Rifamycin is an inhibitor of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6 and 3A4/5 in vitro, however, based on systemic concentrations of rifamycin observed after administration of the recommended dose clinically relevant inhibition of these enzymes in vivo is unlikely.
SUBSTRATE -> METABOLIC ENZYME
TISSUE EXPRESSION -> PARENT
INHIBITOR -> METABOLIC ENZYME
POTENT
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MAJOR
INHIBITOR -> METABOLIC ENZYME
IC50
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
Cobimetinib is a reversible inhibitor of CYP3A4 and CYP2D6 in vitro.
REVERSIBLE
INHIBITOR -> METABOLIC ENZYME
In vitro, lumefantrine significantly inhibits the activity of CYP2D6 at therapeutic plasma concentrations
SUBSTRATE -> METABOLIC ENZYME
MINOR
NON-SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
POTENT
INHIBITOR -> METABOLIC ENZYME
POTENT
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
INHIBITOR -> METABOLIC ENZYME
COMPETITIVE INHIBITOR
Ki
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
SUBSTRATE -> METABOLIC ENZYME
MINOR
Name Property Type Amount Referenced Substance Defining Parameters References
MOL_WEIGHT:NUMBER(CALCULATED) CHEMICAL